- NBC Waiting for Brian Williams Apology as Firing Remains Possible
- Fiat Chrysler CEO Marchionne Possibly on Prowl for a Deal With GM
- It's Time for the Eurozone to Let Greece and Tsipras Go
- 'Star Wars' Crushes 'Batman v. Superman' -- and It's Not Even Close
- $15 Minimum Wage Protests Could Spell Major Problem for Retailers
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Horizon Pharma (HZNP) shares are climbing in after-hours trading today after the company priced its secondary public offering at $28.25 per share.
Hedge Fund Manager Mark Yusko finds select opportunities in the U.S. market in healthcare, airlines and cruise lines, and technology stocks like Netflix (NFLX) and Priceline (PCLN).
Rosetta Genomics (ROSG) shares are up double digits after the company announced that it received a patent for its cancer diagnostic assay.
Mylan's deal to buy Perrigo is taking another potential target off the block.
In which Musk learns how to put a happy spin on failure from biotech CEOs.
Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.
Teva, Actavis and other generics giants may start preying on each other.
BioLife Solutions (BLFS) shares are up double digits after the company released preliminary financial results today.
Johnson & Johnson (JNJ) and Pfizer (PFE) are good stocks to own in a market that is currently overvalued.
Brainstorm Cell Therapeutics (BCLI) shares are gaining as the company prepares to release a report on its phase 2a ALS treatment study.
The bull and bear cases for Gilead's first-quarter earnings hinge on discounts applied to prices of hepatitis C drug Harvoni and Sovaldi.
Advaxis' market value is half as large as competitor Aduro Biotech, which is expected to price its initial public offering on Thursday.
With proxy season coming to a close and corporate annual meeting dates on the horizon, there are several high-profile corporate conflicts that could come down to a shareholder vote.
The verdict on an experimental stem cell therapy developed by Athersys to assist the recovery of stroke patients is coming on April 19.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV